Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02474368 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck
A Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02474368: Active Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic, sponsored by Dana-Farber Cancer Institute.
NCT02474368 is a Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 21 participants, below the 51-participant average among 4 other Recurrent Head and Neck Carcinoma trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02474368, a Phase 1 study of Recurrent Head and Neck Carcinoma and Head and Neck Cancer Metastatic, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of delivering radiation in a more precisely targeted way and with a higher dose than conventional radiotherapy.
Primary Outcome
Cohort 1: patients who have received prior radiation in the head and neck and currently have gross unresectable disease;
Conditions Studied
Interventions
- DRUG Cisplatin
- RADIATION Intensity Modulated Radiation Therapy (IMRT)
- RADIATION Stereotactic Body Radiotherapy (SBRT)
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-11 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What the registry record for NCT02474368 still lists
NCT02474368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 51-participant average among 4 other Recurrent Head and Neck Carcinoma trials with a reported enrollment target (59% lower).
The record links to 3 conditions, with Recurrent Head and Neck Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.
NCT02474368 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02474368 about?
NCT02474368 is a clinical study titled "Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck". This research study seeks to gain new knowledge about the addition of a carefully targeted "boost" dose of radiation as a possible treatment for recurrent or metastatic head or neck cancer. The name of the study intervention involved in this study is stereotactic body radiotherapy, which is a way of...
What is the current status of trial NCT02474368?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-11. Estimated completion is 2026-06.
What conditions does trial NCT02474368 study?
This clinical trial studies the following conditions: Recurrent Head and Neck Carcinoma, Head and Neck Cancer Metastatic, Head or Neck Cancer.
What interventions are being tested in trial NCT02474368?
The interventions under investigation include: Cisplatin (DRUG), Intensity Modulated Radiation Therapy (IMRT) (RADIATION), Stereotactic Body Radiotherapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT02474368?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02474368 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Head and Neck Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)
RECRUITING · NA
-
Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery
COMPLETED · Phase 2
-
Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia